Session » Antiphospholipid Syndrome Poster

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0098

Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0116

Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

10:30AM-12:30PM: Abstract Number: 0100

Association Between the Active Form of Plasminogen Activator Inhibitor 1 (PAI-1) and Endothelial Cell Activation in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0122

Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome

10:30AM-12:30PM: Abstract Number: 0110

Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists

10:30AM-12:30PM: Abstract Number: 0103

CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0119

Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis

10:30AM-12:30PM: Abstract Number: 0111

Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria

10:30AM-12:30PM: Abstract Number: 0128

Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study

10:30AM-12:30PM: Abstract Number: 0112

Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts

10:30AM-12:30PM: Abstract Number: 0125

Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0106

IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS

10:30AM-12:30PM: Abstract Number: 0121

Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers

10:30AM-12:30PM: Abstract Number: 0101

Metabolomic Profiling Reveals a Role for Citric Acid Cycle Dysfunction in Antiphospholipid Syndrome Neutrophils

10:30AM-12:30PM: Abstract Number: 0099

Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0109

Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

10:30AM-12:30PM: Abstract Number: 0105

Novel Autoantibodies Identified in the Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0118

Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort

10:30AM-12:30PM: Abstract Number: 0108

Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)

10:30AM-12:30PM: Abstract Number: 0113

Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

10:30AM-12:30PM: Abstract Number: 0104

Proteomic Analysis Identifies Neutrophil Defensin 1 as a Biological Marker for Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0114

Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

10:30AM-12:30PM: Abstract Number: 0115

Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry

10:30AM-12:30PM: Abstract Number: 0107

Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study

10:30AM-12:30PM: Abstract Number: 0124

Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates

10:30AM-12:30PM: Abstract Number: 0102

Single-cell Profiling of Dermal Endothelial Cells Identifies Unique Molecular Pathways Associated with Small-Vessel Events and Nephropathy in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0129

The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study

10:30AM-12:30PM: Abstract Number: 0123

The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)

10:30AM-12:30PM: Abstract Number: 0126

Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data

10:30AM-12:30PM: Abstract Number: 0127

Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China

10:30AM-12:30PM: Abstract Number: 0117

Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population

10:30AM-12:30PM: Abstract Number: 0120

Vascular Liver Disorders in Patients with Antiphospholipid Syndrome: A Retrospective National Multicentre Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].